GEMINI

 
 

About Gemini

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation.

We have conducted and completed preclinical, Phase 1, and Phase 1b studies and continue to advance Gemini towards FDA approval.

Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications.

Revelation announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity as observed through expected changes in multiple biomarkers including upregulation of IL-10.

The Phase 1b PRIME study demonstrated that Gemini reduced damaging inflammation and corrected immunoparalysis for up to 7 days after a single dose. This correction of immunoparalysis demonstrates Gemini as a non-immunosuppressive agent. The reduction in active inflammation and restoration of immunocompetence supports the potential use of Gemini as an effective treatment for AKI and CKD.

Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two Phase 1 clinical studies.

 
 
 

Lead Gemini Indication: AKI

Acute kidney injury—often called AKI—is a sudden decline in kidney function that can develop within hours or days. It is common in people who are seriously ill, hospitalized or undergoing major surgery, and it may occur without obvious symptoms.

What happens during AKI?

Healthy kidneys remove waste and extra fluid from the blood while helping regulate electrolytes and other essential functions. During AKI, this filtering ability declines quickly.

AKI develops quickly and may be reversible, depending on the cause and severity.

Different causes, one urgent result

Reduced blood flow: Dehydration, bleeding, low blood pressure, severe infection, heart problems or major surgery can reduce the blood reaching the kidneys.

Direct kidney injury: Inflammation, infection and certain medicines or exposures can directly damage kidney tissue.

Blocked urine flow: Kidney stones, prostate enlargement or other structural blockages can prevent urine from leaving the kidneys normally.

Who may be at higher risk?

Risk increases when the kidneys are already vulnerable or the body is under significant stress. Having a risk factor does not mean a person will develop AKI.

✓ Major surgery or low blood pressure

✓ Dehydration or significant fluid loss

✓ Certain medicines or toxic exposures

✓ Urinary tract obstruction

✓ Chronic kidney disease or prior AKI

✓ Diabetes, heart failure or liver disease

✓ Older age or frailty

✓ Sepsis or critical illness

 

Lead Drug Indication: GEM-AKI

GEM-AKI is being developed as a potential therapy for the treatment of acute kidney injury (AKI). We believe redirection of the innate immune response with GEM-AKI from a pro-inflammatory state to an anti-inflammatory (protective) state may rebalance the innate immune response to slow down or halt the progressive destruction and scarring of organ tissue, allowing the healing process to take place.  Preclinical studies conducted by Revelation and our scientific advisors at Vanderbilt have shown that systemic pretreatment with PHAD results in significant protection from AKI. Results from our preclinical study showed the protective effect of IL-10 and NGAL upregulation on the formation of kidney scar tissue in a validated preclinical model of acute and chronic kidney injury.

Acute Kidney Injury, or “AKI”, (also known as acute renal failure), is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease, and death.

AKI is a major cause of morbidity and mortality, affecting more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units. Renal replacement therapy (dialysis) is still the only therapeutic option in the treatment of the consequences of severe AKI and is required in approximately 20% of all critically ill patients. AKI is associated with high mortality rates, and even among those who survive, up to 40% later develop chronic kidney disease or progress to end-stage renal disease. As such, new therapies to treat AKI are urgently needed.

The American Hospital Association states that approximately 34 million people are admitted to US hospitals each year. It was found that 20% or approximately 6.8 million patients admitted to hospitals had AKI by the University of Florida. The CDC says Medicare in 2015 alone had an annual expenditure of over $10 billion and growing for AKI, with spending for AKI related costs of approximately $42,077 per patient. The only treatment for severe AKI is dialysis which increases the potential for worse outcomes including death, therefore Gemini could be the first available therapy for this significant unmet medical need. This data is an indication of how large the AKI market is and the potential for Gemini.

AKI is a serious and growing unmet medical need. Aside from supportive care and the use of renal replacement therapy, there are no approved therapies for treating AKI.

 
 
 

Scientific Presentations